Sökning: WFRF:(Boge Lukas) > Lipid-based nanofor...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03095naa a2200445 4500 | |
001 | oai:DiVA.org:ri-90 | |
003 | SwePub | |
008 | 160428s2016 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:ri:diva-902 URI |
024 | 7 | a https://doi.org/10.1016/j.ijpharm.2016.02.0192 DOI |
040 | a (SwePub)ri | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Matougui, Nadau Inserm, France4 aut |
245 | 1 0 | a Lipid-based nanoformulations for peptide delivery |
264 | 1 | b Elsevier,c 2016 |
338 | a print2 rdacarrier | |
520 | a Nanoformulations have attracted a lot of attention because of their size-dependent properties. Among the array of nanoformulations, lipid nanoformulations (LNFs) have evoked increasing interest because of the advantages of their high degree of biocompatibility and versatility. The performance of lipid nanoformulations is greatly influenced by their composition and structure. Therapeutic peptides represent a growing share of the pharmaceutical market. However, the main challenge for their development into commercial products is their inherent physicochemical and biological instability. Important peptides such as insulin, calcitonin and cyclosporin A have been incorporated into LNFs. The association or encapsulation of peptides within lipid-based carriers has shown to protect the labile molecules against enzymatic degradation. This review describes strategies used for the formulation of peptides and some methods used for the assessment of association efficiency. The advantages and drawbacks of such carriers are also described. | |
650 | 7 | a NATURVETENSKAPx Kemix Annan kemi0 (SwePub)104992 hsv//swe |
650 | 7 | a NATURAL SCIENCESx Chemical Sciencesx Other Chemistry Topics0 (SwePub)104992 hsv//eng |
650 | 7 | a NATURVETENSKAPx Kemix Fysikalisk kemi0 (SwePub)104022 hsv//swe |
650 | 7 | a NATURAL SCIENCESx Chemical Sciencesx Physical Chemistry0 (SwePub)104022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng |
653 | a Drug delivery | |
653 | a Lipids | |
653 | a Nanoformulations | |
653 | a Peptides | |
700 | 1 | a Boge, Lukasu RISE,Life Science4 aut0 (Swepub:ri)lukas.boge@ri.se |
700 | 1 | a Groo, Anne-Claireu Inserm, France4 aut |
700 | 1 | a Umerska, Anitau Inserm, France4 aut |
700 | 1 | a Ringstad, Lovisau RISE,Life Science4 aut |
700 | 1 | a Bysell, Helenau RISE,Life Science4 aut0 (Swepub:ri)helena.bysell@ri.se |
700 | 1 | a Saulnier, Patricku Inserm, France; CHU Angers, France4 aut |
710 | 2 | a Inserm, Franceb Life Science4 org |
773 | 0 | t International Journal of Pharmaceuticsd : Elsevierg 502:1-2, s. 80-97q 502:1-2<80-97x 0378-5173x 1873-3476 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:ri:diva-90 |
856 | 4 8 | u https://doi.org/10.1016/j.ijpharm.2016.02.019 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.